miR-200b/200a/429 Cluster Stimulates Ovarian Cancer Development by Targeting ING5.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
11
2019
revised:
22
01
2020
accepted:
11
02
2020
entrez:
8
5
2020
pubmed:
8
5
2020
medline:
8
5
2020
Statut:
epublish
Résumé
Ovarian cancer is the second most common gynaecological malignancy, and microRNAs (miRNAs) play important role in the cancer development. Here, we found that the level of miR-200b/200a/429 was significantly increased in serum and tumor tissues of patients with stage-I ovarian cancer. Consistent with these results, we detected increased expression levels of miR-200b/200a/429 in ovarian cancer cell lines compared with the human nontumorigenic ovarian epithelial cell line T80. The overexpression of miR-200b/200a/429 in T80 cells stimulated proliferation and caused their growth in soft agar and tumor formation in nude mice. Furthermore, we determined that miR-200b/200a/429 targets inhibitor of growth family 5 (ING5) and that the overexpression of ING5 can block miR-200b/200a/429-induced T80 cell transformation and tumorigenesis. Our findings suggest that miR-200b/200a/429 may be a useful biomarker for the early detection of ovarian cancer and that miR-200b/200a/429 significantly contributes to ovarian cancer development through ING5.
Identifiants
pubmed: 32377191
doi: 10.1155/2020/3404059
pmc: PMC7193301
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3404059Informations de copyright
Copyright © 2020 Wei Guan et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Nat Med. 2011 Aug 07;17(9):1101-8
pubmed: 21822286
Clin Cancer Res. 2008 May 1;14(9):2690-5
pubmed: 18451233
Ultrasound Obstet Gynecol. 2018 Mar;51(3):293-303
pubmed: 28639753
Nucleic Acids Res. 2013 Jan;41(Database issue):D977-82
pubmed: 23180788
Oncotarget. 2017 Oct 19;8(61):103449-103464
pubmed: 29262575
Biochem Biophys Res Commun. 2018 Feb 5;496(2):387-393
pubmed: 29326045
Nat Med. 2011 Nov 20;17(12):1627-35
pubmed: 22101765
Front Oncol. 2019 Apr 11;9:261
pubmed: 31110965
Front Pharmacol. 2016 Aug 23;7:271
pubmed: 27601996
Mol Oncol. 2015 Oct;9(8):1678-93
pubmed: 26025631
Cell. 2013 Jul 18;154(2):311-324
pubmed: 23830207
J Cancer. 2019 Jan 1;10(2):441-448
pubmed: 30719138
Biomed Rep. 2017 Mar;6(3):319-322
pubmed: 28451393
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787